Sab Biotherapeutics, Inc. (SABS) Stock Price & Analysis
Sab Biotherapeutics, Inc. (SABS) fell 1.96% to USD 3.51 as of July 25, 2026 at 06:08 UTC, according to Nexqual real-time market data.
SABS last closed at USD 3.58; the session ranged USD 3.47–3.62 on volume of 954,266 shares. Market capitalization is $268.39M, with a 52-week range of USD 1.85–5.15 (NCM). Source: Nexqual, July 25, 2026 at 06:08 UTC.
Key Statistics (as of July 25, 2026 at 06:08 UTC)
| Price | USD 3.51 |
|---|---|
| Change | ▼ 1.96% (down) |
| Previous Close | USD 3.58 |
| Open | USD 3.59 |
| Day Range | USD 3.47 – 3.62 |
| 52-Week Range | USD 1.85 – 5.15 |
| Volume | 954,266 shares |
| Market Cap | $268.39M |
| Exchange | NCM |
Technical Analysis (SABS)
Nexqual's technical model rates SABS "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:08 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.18 (neutral) |
| vs SMA50 | Below (USD 3.68) |
| MACD | -0.05 (negative) |
Analyst Ratings (SABS)
Wall Street analysts rate SABS "None" based on 11 analysts, with a mean price target of USD 11.18 (range USD 6–16), per Nexqual as of July 25, 2026 at 06:08 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 11.18 |
| High Target | USD 16 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (SABS)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.28 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.41 vs est -0.17 ▼ miss |
| 2025-09-30 | USD 0.5 vs est -0.46 ▲ beat |
| 2025-06-30 | USD -1.09 vs est -0.8 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:08 UTC.
Financials & Fundamentals (SABS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -0.32% |
| Debt / Equity | 2.72 |
| Current Ratio | 11.45 |
| Total Cash | $107.39M |
| Total Debt | $6.17M |
| Free Cash Flow | $-26.64M |
Source: Nexqual, July 25, 2026 at 06:08 UTC.
Financial Health Score (SABS)
Nexqual rates Sab Biotherapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:08 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $107M cash vs $6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$51M |
| Efficiency | Critical — ROE -0%, ROA -25.4% |
Ownership (SABS)
| Insider Ownership | +0.84% |
|---|---|
| Institutional Ownership | +92.43% |
| Shares Outstanding | 76.46M |
| Float | 41.20M |
| Short % of Float | +5.12% |
Source: Nexqual, July 25, 2026 at 06:08 UTC.
Leadership (SABS)
Sab Biotherapeutics, Inc. is led by Samuel J. Reich (age 50), CEO & Director, per Nexqual as of July 25, 2026 at 06:08 UTC.
| CEO & Director | Samuel J. Reich (age 50) |
|---|---|
| Co-Founder, President & Director | Eddie Joe Sullivan (age 58) |
| Executive VP & CFO | Lucy To (age 39) |
| Executive VP & COO | Christoph Bausch (age 54) |
| Vice President of Investor Relations & Corporate Communications | Cristi Barnett |
Major Backers & Investors (SABS)
Notable institutional backers of Sab Biotherapeutics, Inc. include Vivo Capital, LLC, Caligan Partners, LP, Perceptive Advisors Llc, according to Nexqual as of July 25, 2026 at 06:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Vivo Capital, LLC | 14.94% |
| Caligan Partners, LP | 10.42% |
| Perceptive Advisors Llc | 8.41% |
| Commodore Capital Lp | 5.76% |
| RA Capital Management, L.P. | 5.76% |
| Balyasny Asset Management LP | 4.92% |
| Adage Capital Partners GP L.L.C. | 4.45% |
| Millennium Management | 3.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.49% |
Source: Nexqual, July 25, 2026 at 06:08 UTC.
From Sab Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- Proprietary Production Platform Overview Our proprietary production platform gives us the unique ability to generate targeted, hIgG without the need for human donors or plasma.
- Using advanced genetic engineering and antibody science, we developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma.
- Our proprietary platform holds the potential to generate additional novel therapeutic candidates to expand our pipeline, utilizing the human immune response to generate the optimal repertoire of hIgG for drug targets of interest.
- SAFEGUARD, the Company's multicenter, global, randomized, double-blind, placebo-controlled Phase 2b clinical trial, is designed and powered as a registrational program across multiple regions, including the United States, EMA-member states, the United Kingdom, Australia, and New Zealand.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBLG | Bone Biologics Corp | USD 1.07 | ▼ 2.73% |
| REVB | Revelation Biosciences, Inc. | USD 1.06 | ▼ 7.83% |
| ABOS | Acumen Pharmaceuticals, Inc. | USD 2.13 | ▼ 3.62% |
| SRZN | Surrozen, Inc. | USD 19.73 | ▼ 9.16% |
| INAB | IN8bio, Inc. | USD 1.2 | ▼ 2.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:08 UTC. This page is informational and not investment advice.